Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 28, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - January 28, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/28/15 - AbbVie Announces U.S. FDA Approval of DUOPA? carbidopa and levodopa Enteral Suspension for the Treatment of Motor Fluctuations in Patients with...
By a News Reporter-Staff News Editor at Biotech Week The U.S. Food and Drug Administration has approved AbbVie's DUOPA? enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare dis
1/28/15 - Antares Pharma Announces Update to QuickShot Testosterone Program
The Company believes that it has already factored many of the recommendations cited in the advice letter into the protocol of the ongoing phase 3 study and into the protocols for planned human use studies as a result of guidance provided by FDA at the May 2014 Type C meeting. Based on a single reported occurrence of hives in the Company's phase 2 s
1/28/15 - Array Biopharma Given New $9.00 Price Target at Stifel Nicolaus (ARRY) [Jerusalem Post (Israel)]
Equities researchers at Stifel Nicolaus raised their price objective on shares of Array Biopharma from $6.00 to $9.00 in a research report issued on Monday. Analysts at Zacks downgraded shares of Array Biopharma from an outperform rating to a neutral rating and set a $5.20 price target on the stock in a research note on Tuesday, January
1/28/15 - Bellicum Pharmaceuticals Announces Successful Dosing of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell...
By a News Reporter-Staff News Editor at Biotech Week Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, announced that the first cohort of patients in the BP-004 trial has completed dosing with the Company's genetically engineered donor T cells, after...
1/28/15 - BioPharma Services is Pleased to Announce Dr. Janice Faulknor as Their New Dedicated Medical Director
By a News Reporter-Staff News Editor at Biotech Week BioPharma Services Inc. is pleased to announce that Dr. Dr. Faulknor has held senior medical roles within Pharmaceutical Contract Research Organizations, responsible for Phase 1, SAD-MAD, and Bioequivalence studies, at CRO organizations including INC Research. "About BioPharma Services Inc.: B
1/28/15 - bioTheranostics Appoints Key Executives to Leadership Team
By a News Reporter-Staff News Editor at Biotech Week bioTheranostics, Inc., a leader in molecular diagnostics for cancer, announced the addition of two industry veterans to its senior management team as the company focuses on further commercial expansion of its Breast Cancer IndexSM molecular test. Jennifer Skeen, Ph.D., joins bioTheranostics as
1/28/15 - Cancer patients look to India for lifesaving drugs [China Daily: Africa Weekly]
Leukemia patient Lu Yong borrowed the idea from the Oscar-winning film Dallas Buyers Club and smuggled unapproved, Indian-made drugs for himself and 1,000 others to get medicines at an affordable price. In China, a month's supply of Gleevec costs more than 23,000 yuan, and it is not covered by health insurance in most places. However, any unapprove
1/28/15 - Cancer patients look to India for lifesaving drugs [China Daily: Hong Kong Edition]
In China, a month's supply of Gleevec costs more than 23,000 yuan, and it is not covered by health insurance in most places. Lu gave up on a transplant because donors are hard to find in China, and a transplant also carries the risk of potential major side effects. However, any unapproved medications are illegal in China, and the China Food and Dru
1/28/15 - Cellceutix Released Results of Phase 2b Clinical Trial of Brilacidin [Health & Beauty Close - Up]
Cellceutix Corp. reported that results of its recently completed phase 2 b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin& Skin Structure Infections" will be given in an oral presentation at the European Congress of Clinical Microbiology and..
1/28/15 - Cti Biopharma Corp. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jan. 9, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on January 9, 2015. The SEC file number is 0000891293-15-000002.. A U.S. Securities and Exchange Commission filing is a formal
1/28/15 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report (Jan. 13, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on January 13, 2015. The SEC file number is 0001193125-15-008685.. A U.S. Securities and Exchange Commission filing is a forma
1/28/15 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report (Jan. 9, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on January 9, 2015. The SEC file number is 0001564590-15-000094.. A U.S. Securities and Exchange Commission filing is a formal
1/28/15 - Cti Biopharma Corp. Files SEC Form DEF 14A, Other Definitive Proxy Statements (Jan. 14, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on January 14, 2015. The SEC file number is 0001193125-15-010809.. A U.S. Securities and Exchange Commission filing is a forma
1/28/15 - Cure Duchenne Seeds Collaborative Project to Analyze the Natural History of Duchenne Muscular Dystrophy
Susan J. Ward, a consultant to BioPharma, in partnership with Dr. James Signorovitch, Vice President at Analysis Group Inc., on a collaborative project to further the understanding of the natural history of Duchenne muscular dystrophy. "Three companies are seeking FDA approval for Duchenne drugs next year, and others will be designing pivotal clin
1/28/15 - Cure Duchenne Ventures LLC To Provide $1 Million to Capricor Therapeutics to Advance Promising Research to Treat Heart Disease Associated with...
Cure Duchenne Ventures LLC To Provide $1 Million to Capricor Therapeutics to Advance Promising Research to Treat Heart Disease Associated with Duchenne Muscular Dystrophy. By a News Reporter-Staff News Editor at Biotech Week CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy that was formed by
1/28/15 - DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083
By a News Reporter-Staff News Editor at Biotech Week DelMar Pharmaceuticals, Inc. announced that the U.S. DelMar will provide an update on the Company's ongoing Phase I/II glioblastoma clinical trial with VAL-083 during DelMar's presentation at the Biotech Showcase Conference tomorrow at 1:45 PM Pacific Time. Keywords for this news article includ
1/28/15 - Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads
By a News Reporter-Staff News Editor at Journal of Engineering Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, announced that the United States Patent and Trademark Office issued to Dicerna Patent No. 8,927,705, "Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expres
1/28/15 - Ebolanomics - the Search for a Vaccine
When Ebola hit West Africa last year, it was a disease with no sign of a vaccine or cure. Yet now pharmaceutical companies are racing to produce an effective vaccine, and on 23 January the British company Glaxo Smith Kline shipped the first 300 doses of its candidate to Liberia to start phase II trials. At an event in the UK Houses of Parliament to
1/28/15 - Exploring the Global Pharmaceuticals Industry Outlook to Reinforce Health Standards at 300+ OMICS International Annual Events
The sales of drug-device combination products were reached $21.4 billion in 2013 and $22 billion in 2014. This is expected to grow up to $31 billion in 2019, with a compound annual growth rate of 7.1%. North America region is the largest in generating the revenues because of U.S. pharmaceutical industry where as the European-based pharmaceutical in
1/28/15 - FACE Skincare Medical Wellness Introduces New FDA Approved Bellafill for the Treatment of Acne Scars
Recently approved by the FDA, the collagen gel in Bellafill provides immediate volume and lift using PMMA microspheres, one of the most widely used materials in medicine for 65 years. According to a recent article published on January 6, 2015, the FDA action was based on a randomized study at 10 U.S. clinical centers in which Bellafill was "foun
1/28/15 - FDA Approves Novartis' Bexsero [Health & Beauty Close - Up]
The U.S. Food and Drug Administration reported the approval of Novartis' Bexsero for the prevention of serogroup B meningococcal disease in individuals ages 10 to 25.. According to a media release, Bexsero and Pfizer's vaccine Trumenba, which received FDA approval in October, represent a significant step forward in helping prevent this devastating
1/28/15 - FDA Grants Accelerated Approval of Novartis' Bexsero Vaccine [Health & Beauty Close - Up]
Novartis reported that the US Food and Drug Administration has granted accelerated approval of Bexsero for active immunization to prevent invasive meningococcal disease caused by serogroup B in adolescents and young adults from 10 years through 25 years of age. As part of the accelerated approval process, Novartis will complete its ongoing studies
1/28/15 - First contracting human muscle grown in laboratory
By a News Reporter-Staff News Editor at Journal of Engineering DURHAM, N.C. In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals. The study was led by Nenad Bursac, associate professor of
1/28/15 - Gates defends big drug companies against criticism of vaccine prices: Lower prices would mean less research, MSF is told Immunisation described as highly cost-effective
Bill Gates has dismissed criticism by campaigners of the high prices of some vaccines, warning that it only serves to deter pharmaceutical companies from working on lifesaving products for poor countries. At the pledging meeting for Gavi, the global vaccines alliance, hosted by German chancellor Angela Merkel, they organised a stunt featuring suppo
1/28/15 - Immune Therapeutics Inc. Announces Appointment of New President and Chief Operating Officer
By a News Reporter-Staff News Editor at Biotech Week Immune Therapeutics Inc., a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, announced the...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part I: Cardiovascular Disorders
This lesson is supported by:
RxSchool
Workplace Safety & Joint Commission Standards for Pharmacy Professionals
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415